ArticleClinical ophthalmology (Auckland, N.Z.)2025
Visual Outcomes and Safety Profile of "Dropless Vitrectomy" for Epiretinal Membranes.
Article in Clinical ophthalmology (Auckland, N.Z.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To assess the clinical effectiveness and safety of Tri-Moxi intravitreal injection in comparison to standard postoperative topical steroid-antibiotic treatment after epiretinal membrane (ERM) removal with pars plana vitrectomy (PPV). Methods: A retrospective longitudinal cohort study of 278 eyes undergoing ERM removal by PPV was conducted from 2019 to 2023. Group 1 (N = 139) received a triamcinolone acetonide-moxifloxacin (Tri-Moxi) intravitreal injection at the conclusion of surgery, and Group 2 (N = 139) had postoperative standard topical antibiotic-steroid therapy. Clinical changes of best-corrected visual acuity (BCVA), intraocular pressure (IOP), and central foveal thickness (CFT) were evaluated. Results: By 3-month after surgery, the Tri-Moxi (Group 1) demonstrated a significantly greater reduction in CFT (178 ± 32 vs 145 ± 38 µm, P < 0.001) and a slightly superior improvement in BCVA (0.34 ± 0.03 vs 0.41 ± 0.04 logMAR, P < 0.05) compared to the standard (Group 2). Postoperative IOP remained minimal change in both groups. The occurrence of cystoid macular edema was markedly reduced in patients receiving Tri-Moxi (4% vs 10%, P = 0.02). No infection or ocular hypertension cases were recorded. Conclusion: For the postoperative management of PPV in ERM patients, intravitreal Tri-Moxi injection is an efficacious and safe alternative to standard topical therapy. Intravitreal Tri-Moxi can be used as a viable treatment option for managing inflammation and preventing infection after epiretinal membrane removal by pars plana vitrectomy. Tri-Moxi group demonstrated superior anatomical outcomes and comparable functional outcomes while simplifying postoperative care and reducing the occurrence of cystoid macular edema compared to standard topical therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.